Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 3135a is a short (~20-24 nucleotide) non-coding RNA classified as a human microRNA (miRNA)[1][3]. MicroRNAs are transcribed primarily by RNA polymerase II as part of longer primary transcripts (pri-miRNAs), which are cleaved in the nucleus by Drosha to generate precursor miRNAs. These are exported to the cytoplasm, further processed by Dicer, and the mature miRNA is then loaded onto the RISC complex, which targets specific mRNAs by imperfect base pairing, resulting in gene silencing via translational inhibition or mRNA destabilization[1][6][7]. While thousands of microRNAs are cataloged in the human genome, current literature on MIR3135A identifies an association with autism spectrum disorder, but detailed regulatory targets, interacting drugs, or mechanistic therapeutic roles are largely unknown.
Not directly targeted by drugs; general microRNA mechanism involves incorporation into the RNA-induced silencing complex (RISC), which binds to complementary sequences on target mRNAs to inhibit their translation or promote their degradation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 3135a (MIR3135A).